Monic J. Stuart

2.0k total citations
26 papers, 1.5k citations indexed

About

Monic J. Stuart is a scholar working on Hematology, Genetics and Oncology. According to data from OpenAlex, Monic J. Stuart has authored 26 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Hematology, 7 papers in Genetics and 7 papers in Oncology. Recurrent topics in Monic J. Stuart's work include Hematopoietic Stem Cell Transplantation (10 papers), Acute Myeloid Leukemia Research (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Monic J. Stuart is often cited by papers focused on Hematopoietic Stem Cell Transplantation (10 papers), Acute Myeloid Leukemia Research (8 papers) and Chronic Myeloid Leukemia Treatments (7 papers). Monic J. Stuart collaborates with scholars based in United States, Germany and Switzerland. Monic J. Stuart's co-authors include Karl G. Blume, Michael B. Maris, Brenda M. Sandmaier, David G. Maloney, Rainer Storb, Thomas R. Chauncey, Barry E. Storer, Michael A. Pulsipher, Judith A. Shizuru and Keith Stockerl‐Goldstein and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Oncology and Blood.

In The Last Decade

Monic J. Stuart

25 papers receiving 1.5k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Monic J. Stuart United States	15	953	456	443	431	379	26	1.5k
Alberto M. Marmont Italy	23	1.0k 1.1×	345 0.8×	525 1.2×	310 0.7×	319 0.8×	66	1.7k
Sławomira Kyrcz‐Krzemień Poland	21	906 1.0×	279 0.6×	345 0.8×	284 0.7×	169 0.4×	115	1.4k
Don Milligan United Kingdom	13	637 0.7×	384 0.8×	312 0.7×	327 0.8×	369 1.0×	26	1.1k
J. Mittermüller Germany	16	1.3k 1.3×	311 0.7×	858 1.9×	637 1.5×	136 0.4×	35	2.0k
Michael J. Clemente United States	20	412 0.4×	469 1.0×	773 1.7×	217 0.5×	376 1.0×	67	1.5k
Ram Malladi United Kingdom	20	935 1.0×	156 0.3×	442 1.0×	366 0.8×	166 0.4×	64	1.4k
Jeffrey Schriber United States	13	744 0.8×	218 0.5×	324 0.7×	333 0.8×	138 0.4×	22	1.1k
Ángel León Spain	14	1.1k 1.2×	253 0.6×	364 0.8×	405 0.9×	328 0.9×	21	1.6k
Maurizio Miglino Italy	18	737 0.8×	260 0.6×	291 0.7×	319 0.7×	99 0.3×	65	1.1k
Athanasios Zomas Greece	18	852 0.9×	366 0.8×	207 0.5×	443 1.0×	303 0.8×	55	1.3k

Countries citing papers authored by Monic J. Stuart

Since Specialization

Citations

This map shows the geographic impact of Monic J. Stuart's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Monic J. Stuart with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Monic J. Stuart more than expected).

Fields of papers citing papers by Monic J. Stuart

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Monic J. Stuart. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Monic J. Stuart. The network helps show where Monic J. Stuart may publish in the future.

Co-authorship network of co-authors of Monic J. Stuart

This figure shows the co-authorship network connecting the top 25 collaborators of Monic J. Stuart. A scholar is included among the top collaborators of Monic J. Stuart based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Monic J. Stuart. Monic J. Stuart is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Roboz, Gail J., Ahmed Aribi, Adrian F. Ochsenbein, et al.. (2024). Trial in Progress: A Multicenter, Open Label, Randomized, Phase 2 Study of Venetoclax and Azacitidine Plus Cusatuzumab Versus Venetoclax and Azacitidine Alone in Newly Diagnosed AML Patients Who Are Not Candidates for Intensive Therapy. Blood. 144(Supplement 1). 1504.2–1504.2.

Hernandez‐Ilizaliturri, Francisco J., Ian W. Flinn, John Kuruvilla, et al.. (2020). A Phase I Pharmacokinetic (PK) and Safety Study of Trph-222 in Patients with Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (R/R NHL): Dose-Escalation Results. Blood. 136(Supplement 1). 41–42. 12 indexed citations

Baerlocher, Gabriela M., Elisabeth Oppliger Leibundgut, Oliver G. Ottmann, et al.. (2015). Telomerase Inhibitor Imetelstat in Patients with Essential Thrombocythemia. New England Journal of Medicine. 373(10). 920–928. 149 indexed citations

Tefferi, Ayalew, Kebede H. Begna, Rebecca R. Laborde, et al.. (2013). Imetelstat, a Telomerase Inhibitor, Induces Morphologic and Molecular Remissions In Myelofibrosis and Reversal Of Bone Marrow Fibrosis. Blood. 122(21). 662–662. 17 indexed citations

Huff, Carol Ann, Ashraf Badros, Richard J. Jones, et al.. (2012). The Telomerase Inhibitor, Imetelstat, Rapidly Reduces Myeloma Cancer Stem Cells (CSCs) in a Phase II Trial. Blood. 120(21). 4898–4898. 4 indexed citations

Baerlocher, Gabriela M., Elisabeth Oppliger Leibundgut, Martha Blaney, et al.. (2012). Imetelstat Rapidly Induces and Maintains Substantial Hematologic and Molecular Responses in Patients with Essential Thrombocythemia (ET) Who Are Refractory or Intolerant to Prior Therapy: Preliminary Phase II Results. Blood. 120(21). 179–179. 13 indexed citations

Sledge, G. W., et al.. (2010). Phase I study of imetelstat (GRN163L) in combination with paclitaxel (P) and bevacizumab (B) in patients (pts) with locally recurrent or metastatic breast cancer (MBC).. Journal of Clinical Oncology. 28(15_suppl). 2598–2598. 18 indexed citations

Laport, Ginna G., Brenda M. Sandmaier, Barry E. Storer, et al.. (2008). Reduced-Intensity Conditioning followed by Allogeneic Hematopoietic Cell Transplantation for Adult Patients with Myelodysplastic Syndrome and Myeloproliferative Disorders. Biology of Blood and Marrow Transplantation. 14(2). 246–255. 97 indexed citations

Baron, Frédéric, Michael B. Maris, Barry E. Storer, et al.. (2005). HLA-matched unrelated donor hematopoietic cell transplantation after nonmyeloablative conditioning for patients with chronic myeloid leukemia. Biology of Blood and Marrow Transplantation. 11(4). 272–279. 41 indexed citations

10.

Maris, Michael B., Brenda M. Sandmaier, Barry E. Storer, et al.. (2004). Allogeneic Hematopoietic Cell Transplantation after Fludarabine and 2 Gy Total Body Irradiation for Relapsed and Refractory Mantle Cell Lymphoma.. Blood. 104(11). 809–809. 7 indexed citations

11.

Cao, Thai M., Judith A. Shizuru, Ruby M. Wong, et al.. (2004). Engraftment and survival following reduced-intensity allogeneic peripheral blood hematopoietic cell transplantation is affected by CD8+ T-cell dose. Blood. 105(6). 2300–2306. 50 indexed citations

12.

Johnston, Laura, J. Martin Brown, Judith A. Shizuru, et al.. (2004). Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease. Biology of Blood and Marrow Transplantation. 11(1). 47–55. 93 indexed citations

13.

Cao, Thai M., Judith A. Shizuru, Ruby M. Wong, et al.. (2004). Engraftment and Survival Following Non-Myeloablative Allogeneic Peripheral Blood Hematopoietic Cell Transplantation for Malignant Diseases Is Affected by CD8+ T-Cell Dose.. Blood. 104(11). 183–183. 1 indexed citations

14.

Niederwieser, Dietger, Ute Hegenbart, Brenda M. Sandmaier, et al.. (2004). Treatment for Acute Myelogenous Leukemia by Low Dose Irradiation Based Conditioning and Hematopoietic Cell Transplantation from Related and Unrelated Donors.. Blood. 104(11). 3074–3074. 5 indexed citations

15.

Sandmaier, Brenda M., David G. Maloney, Michael B. Maris, et al.. (2003). Allografting after nonmyeloablative conditioning as a treatment after a failed conventional hematopoietic cell transplant. Biology of Blood and Marrow Transplantation. 9(4). 266–272. 21 indexed citations

16.

Bethge, Wolfgang, Ute Hegenbart, Monic J. Stuart, et al.. (2003). Adoptive immunotherapy with donor lymphocyte infusions after allogeneic hematopoietic cell transplantation following nonmyeloablative conditioning. Blood. 103(3). 790–795. 104 indexed citations

17.

Horwitz, Sarah McCue, Robert S. Negrin, Karl G. Blume, et al.. (2003). Rituximab as adjuvant to high-dose therapy and autologous hematopoietic cell transplantation for aggressive non-Hodgkin lymphoma. Blood. 103(3). 777–783. 158 indexed citations

18.

Stuart, Monic J., William P. Peters, Gloria Broadwater, et al.. (2002). High-dose chemotherapy and hematopoietic support for patients with high-risk primary breast cancer and involvement of 4 to 9 lymph nodes. Biology of Blood and Marrow Transplantation. 8(12). 666–673. 3 indexed citations

19.

Stuart, Monic J., Nelson J. Chao, Sandra J. Horning, et al.. (2001). Efficacy and toxicity of a CCNU-containing high-dose chemotherapy regimen followed by autologous hematopoietic cell transplantation in relapsed or refractory Hodgkin's disease. Biology of Blood and Marrow Transplantation. 7(10). 552–560. 17 indexed citations

20.

Marom, Edith M., Yo Won Choi, Scott M. Palmer, et al.. (2001). Reperfusion Edema after Lung Transplantation: Effect of Daclizumab. Radiology. 221(2). 508–514. 12 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact